# Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

Clinical trial · Karuna Therapeutics, Inc., a Bristol Myers Squibb company

- Archive id: nct:NCT07686263
- Published: 2026-07-07
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07686263
- Source URL: https://clinicaltrials.gov/study/NCT07686263
- Provenance: clinicaltrials

## Abstract

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 472
- sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- conditions: Schizophrenia
- interventions: DRUG: Xanomeline/Trospium Chloride; DRUG: Placebo
- start date: 2026-08-20
- start date type: ACTUAL
- primary completion date: 2029-03-03
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Novel Psychiatric Therapeutics](https://space-kitty.com/topics/psychiatric-therapeutics)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.